Apogee Therapeutics, Inc. (APGE) has issued an update.
Apogee Therapeutics, Inc. has released exciting initial Phase 1 data for APG777, a groundbreaking first-in-human study. This new development could be a game-changer for investors and industry watchers, as the data is now available for public viewing on the company’s website. The implications of this study are significant for the future of Apogee Therapeutics and its position in the biotech market.
For detailed information about APGE stock, go to TipRanks’ Stock Analysis page.
